​

Arcutis Biotherapeutics Ownership | Who Owns Arcutis Biotherapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Arcutis Biotherapeutics Ownership Summary

Arcutis Biotherapeutics is owned by 26.93% institutional investors, 1.67% insiders, and 71.40% retail investors. Suvretta capital management is the largest institutional shareholder, holding 8.25% of ARQT shares. Polar Capital Biotech S Inc is the top mutual fund, with 4.17% of its assets in Arcutis Biotherapeutics shares.

ARQT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockArcutis Biotherapeutics26.93%1.67%71.40%
SectorHealthcare Stocks 232.51%10.72%-143.23%
IndustryBiotech Stocks 384.56%10.58%-295.14%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Suvretta capital management10.48M8.25%$197.51M
Frazier life sciences management9.87M7.78%$186.13M
Blackrock8.62M7.76%$80.19M
Blackrock funding, inc. /de9.10M7.13%$264.25M
Rubric capital management lp8.27M6.48%$240.21M
Vanguard group7.25M5.68%$210.65M
Jennison associates6.76M5.30%$196.25M
Polar capital5.30M4.17%$99.88M
State street4.64M3.65%$87.49M
Gilder gagnon howe4.43M3.49%$83.49M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Pivotal bioventure partners investment advisor2.12M23.11%$39.97M
Frazier life sciences management9.87M5.58%$186.13M
Suvretta capital management10.48M5.06%$197.51M
Lion point capital, lp35.30K3.78%$665.40K
Rubric capital management lp8.27M2.87%$240.21M
Ally bridge group (ny)233.22K2.68%$4.40M
Myda advisors470.00K1.91%$8.86M
Privium fund management b.v.305.97K1.64%$8.89M
Stempoint capital lp411.89K1.56%$7.76M
Fishman jay a ltd/mi564.65K1.35%$16.40M

Top Buyers

HolderShares% AssetsChange
Blackrock8.62M0.00%1.96M
Millennium management2.31M0.02%1.16M
Voloridge investment management833.49K0.05%833.49K
D. e. shaw2.51M0.03%768.55K
Bnp paribas arbitrage, snc699.80K0.01%653.66K

Top Sellers

HolderShares% AssetsChange
Jennison associates6.76M0.12%-5.50M
Rubric capital management lp8.27M2.87%-2.48M
Point72 asset management---1.49M
Paradigm biocapital advisors lp---1.47M
Perceptive advisors---1.36M

New Positions

HolderShares% AssetsChangeValue
Zevenbergen capital investments418.04K0.27%418.04K$12.14M
Renaissance274.00K0.01%274.00K$7.96M
Ally bridge group (ny)233.22K2.68%233.22K$4.40M
Eam investors213.86K0.69%213.86K$6.21M
Patient square capital lp210.00K1.31%210.00K$6.10M

Sold Out

HolderChange
Twin peaks wealth advisors-2.00
Nelson, van denburg & campbell wealth management group-22.00
Stephens consulting-25.00
Amundi-66.00
Gps wealth strategies group-80.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 2025127-48.79%34,362,908-72.69%260.27%72-40.98%38-54.22%
Sep 30, 202587-63.14%29,200,444-76.92%220.23%44-63.64%25-62.69%
Jun 30, 2025234-6.02%126,474,0751.16%991.01%120-6.25%66-20.48%
Mar 31, 202524613.36%124,963,282-3.01%990.92%12716.51%8122.73%
Dec 31, 20242149.74%120,033,596-6.58%960.90%1073.88%6629.41%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Polar Capital Biotech S Inc5.00M4.17%-
Vanguard US Total Market Shares ETF3.59M3.03%492.10K
Vanguard Total Stock Mkt Idx Inv3.39M2.83%-71.75K
Jennison SMid Cap Core Equity3.17M2.66%83.01K
PGIM Jennison Small Company A3.17M2.64%9.07K
iShares Russell 2000 ETF2.58M2.15%-
Jennison Health Sciences Equity2.27M1.90%-
PGIM Jennison Health Sciences Z2.27M1.89%-
SPDR® S&P Biotech ETF1.88M1.57%4.20K
Franklin Biotechnology Discv A(acc)USD1.61M1.34%-77.76K

Recent Insider Transactions

DateNameRoleActivityValue
Feb 02, 2026Matsuda Masaru See RemarksSell$120.82K
Feb 02, 2026Matsuda Masaru See RemarksSell$213.79K
Feb 02, 2026Matsuda Masaru See RemarksSell$489.13K
Feb 02, 2026Matsuda Masaru See RemarksSell$203.55K
Feb 02, 2026Burnett Patrick See RemarksSell$93.71K

Insider Transactions Trends

DateBuySell
2026 Q1-12
2025 Q4-32
2025 Q3-15
2025 Q2910
2025 Q1-18

ARQT Ownership FAQ

Who Owns Arcutis Biotherapeutics?

Arcutis Biotherapeutics shareholders are primarily institutional investors at 26.93%, followed by 1.67% insiders and 71.40% retail investors. The average institutional ownership in Arcutis Biotherapeutics's industry, Biotech Stocks , is 384.56%, which Arcutis Biotherapeutics falls below.

Who owns the most shares of Arcutis Biotherapeutics?

Arcutis Biotherapeutics’s largest shareholders are Suvretta capital management (10.48M shares, 8.25%), Frazier life sciences management (9.87M shares, 7.78%), and Blackrock (8.62M shares, 7.76%). Together, they hold 23.79% of Arcutis Biotherapeutics’s total shares outstanding.

Does Blackrock own Arcutis Biotherapeutics?

Yes, BlackRock owns 7.76% of Arcutis Biotherapeutics, totaling 8.62M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 80.19M$. In the last quarter, BlackRock increased its holdings by 1.96M shares, a 29.49% change.

Who is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Pivotal bioventure partners investment advisor is Arcutis Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 23.11% of its assets in 2.12M Arcutis Biotherapeutics shares, valued at 39.97M$.

Who is the top mutual fund holder of Arcutis Biotherapeutics shares?

Polar Capital Biotech S Inc is the top mutual fund holder of Arcutis Biotherapeutics shares, with 4.17% of its total shares outstanding invested in 5M Arcutis Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools